Friday, January 07, 2022 7:52:42 AM
5:07 am ET January 7, 2022 (Benzinga) Print
Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Absci's AI-powered Integrated Drug Creation™ Platform.
Under the collaboration, Absci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck's biomanufacturing applications and receive an upfront and certain other milestone payments. In addition, Merck has the option to nominate up to three targets and enter into a drug discovery collaboration agreement, and Absci would then be eligible to receive up to $610 million in upfront fees and milestone payments for all three targets, as well as research funding and tiered royalties on sales.
Sean McClain, founder and CEO of Absci, commented, "We are very pleased to establish this collaboration with Merck and to be working with its world class research organization to generate novel enzymes. We look forward to applying our AI-driven platform to create new biologic candidates with the potential to meaningfully improve the lives of patients."
"At Merck we are continually evaluating new ways to build, expand and refine our biologics capabilities," said Dr. Fiona Marshall, senior vice president and head of discovery, preclinical and translation medicine, Merck Research Laboratories. "Absci's platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins."
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
New York Yankees and Duke Basketball
Recent ABSI News
- Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 11:35:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:32:37 AM
- Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 03/01/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:06:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 01:34:42 PM
- Absci Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 02/28/2024 03:20:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:45:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 09:40:17 PM
- Absci Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 02/27/2024 09:01:00 PM
- Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI • GlobeNewswire Inc. • 02/21/2024 12:30:00 PM
- Absci to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 11:16:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:14:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:14:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:12:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:09:28 AM
- Absci Appoints Professor Sir Mene Pangalos to its Board of Directors • GlobeNewswire Inc. • 01/10/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:08:52 PM
- Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:58:34 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM